WaveMan
WaveMan · Company
STXS · Stereotaxis, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

STXS Stereotaxis (STXS) Insider Trading, Ownership & Congress Trades

Medical Devices · Electromedical & electrotherapeutic apparatus · CIK 0001289340
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
59
13F, latest reported quarter

Stereotaxis insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Stereotaxis, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Isaac Paul J
Director
BUY
2025-11-18 SECtraded 2025-11-17
10,000
$21.8K
-55.8%
Context
  • 48 earlier Form 4 trades (code P or S) here by this insider (48 buys), the last on Nov 14, 2025.
  • +18.5% median (+34.2% mean) 90-day return after 30 previous buys.
  • The trade is 10.3% of the 97,299 shares held after it.
  • No other insider bought within 30 days.
  • 59 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Isaac Paul J bought about $21.8K of STXS on Nov 17, 2025; 59 funds added in the latest 13F quarter.
Isaac Paul J
Director
BUY
2025-11-18 SECtraded 2025-11-14
20,000
$44.8K
-55.8%
Context
  • 47 earlier Form 4 trades (code P or S) here by this insider (47 buys), the last on Mar 10, 2025.
  • +18.5% median (+34.0% mean) 90-day return after 30 previous buys.
  • The trade is 0.7% of the 2,786,557 shares held after it.
  • No other insider bought within 30 days.
  • 59 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Isaac Paul J bought about $44.8K of STXS on Nov 14, 2025; 59 funds added in the latest 13F quarter.
Isaac Paul J
Director
BUY
2025-03-11 SECtraded 2025-03-10
38,000
$68.8K
-45.9%
Context
  • 46 earlier Form 4 trades (code P or S) here by this insider (46 buys), the last on Mar 7, 2025.
  • +17.7% median (+32.8% mean) 90-day return after 30 previous buys.
  • The trade is 43.5% of the 87,299 shares held after it.
  • No other insider bought within 30 days.
  • 59 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Isaac Paul J bought about $68.8K of STXS on Mar 10, 2025, the largest insider purchase at the company since 2022; 59 funds added in the latest 13F quarter.
Isaac Paul J
Director
BUY
2025-03-10 SECtraded 2025-03-07
1,489
$2.7K
-44.7%
Context
  • 45 earlier Form 4 trades (code P or S) here by this insider (45 buys), the last on Mar 6, 2025.
  • +16.4% median (+31.9% mean) 90-day return after 30 previous buys.
  • The trade is 0.1% of the 2,766,557 shares held after it.
  • No other insider bought within 30 days.
  • 59 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Isaac Paul J bought about $2.7K of STXS on Mar 7, 2025; 59 funds added in the latest 13F quarter.
Isaac Paul J
Director
BUY
2025-03-10 SECtraded 2025-03-06
23,299
$42.2K
-44.7%
Context
  • 44 earlier Form 4 trades (code P or S) here by this insider (44 buys), the last on Aug 20, 2024.
  • +12.7% median (+30.7% mean) 90-day return after 30 previous buys.
  • The trade is 47.5% of the 49,066 shares held after it.
  • No other insider bought within 30 days.
  • 59 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Isaac Paul J bought about $42.2K of STXS on Mar 6, 2025, the largest insider purchase at the company since 2022; 59 funds added in the latest 13F quarter.
49 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 44 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
59 funds bought in last quarter
below 53% of Medical Devices
Revenue
+20.3% year over year
more than 73% of Medical Devices
Margin
-66.8% net margin
below 73% of Medical Devices
Buybacks
no share repurchases reported
Short interest
9.1% of the float short (float per yahoo 2026-10-27) · 10.2 days to cover · settled 2026-10-15
more than 71% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch STXS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-68.1%12M
-68%-45%-23%+0%2025-102025-122026-022026-042026-062026-082026-10 2025-11-14 · Isaac Paul J bought $44.8K2025-11-17 · Isaac Paul J bought $21.8K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns STXS: institutional holders (13F)

13F holdings, latest reported quarter
DAFNA Capital Management LLC
13,680,554 sh
$23.5M
Arbiter Partners Capital Management LLC
5,767,712 sh
$9.9M
BlackRock, Inc.
4,396,835 sh
$7.6M
Lagoda Investment Management, L.P.
4,122,600 sh
$7.1M
VANGUARD CAPITAL MANAGEMENT LLC
3,044,820 sh
$5.2M

Congress trades in STXS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

STXS planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

STXS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
AlphaCentric Robotics and Automation Fund
$1.0M position · as of 2026-06-30
3.9%
Ultra-Small Company Market Fund
$218.6K position · as of 2026-06-30
0.1%
Ultra-Small Company Fund
$55.7K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$393.0K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$26.5K position · as of 2026-06-30
0.0%
iShares Russell 2000 Growth ETF
$1.1M position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · David Fischel
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$64.4K
-$2.0M
$326.1K
+11%
n/a
2024
$62.2K
$3.7M
$340.2K
+12%
n/a
2023
$62.2K
-$4.3M
$323.8K
-15%
n/a
2022
$62.2K
-$49.1M
$386.8K
-67%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 59 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

STXS financials

Revenue growth
+20.3%
XBRL, annual
Net margin
-66.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$30.1M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-74.2%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$15.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.18x
long-term 2021-03-31 (63 months older than the period end) plus current 2021-03-31 (63 months older than the period end); equity 2026-06-30
Cash flow to debt
-7.08x
TTM operating cash flow over long-term 2021-03-31 (63 months older than the period end) plus current 2021-03-31 (63 months older than the period end)
Return on equity
-325.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-46.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-92.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$90.9M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2021-03-31 (63 months older than the period end) plus current 2021-03-31 (63 months older than the period end), minus cash 2026-06-30
FCF yield
-15.6%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$32.4M$26.9M$26.8M$28.1M
Gross profit$17.1M$14.6M$14.9M$18.5M
Operating income-$22.1M-$24.7M-$21.8M-$18.8M
Net income-$21.6M-$24.0M-$20.7M-$18.3M
EPS (diluted)-0.25-0.30-0.27-0.26
Operating cash flow-$13.7M-$8.5M-$9.1M-$8.4M
Cash$13.4M$12.2M$19.8M$8.6M
Dividends paid$0$0$0$0
SEC XBRL, fiscal years, as known on 2026-10-28

STXS Stock Sonar score 5/7 axes

Find similar shapesCompare

STXS ranks highest on risk and compliance (53rd percentile) and institutional and government (47th), and lowest on profitability (21st), among Medical Devices peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
21
Inputs
  • Return on equity-325.9% · 9 pct, sector of 183
  • Return on assets-46.1% · 33 pct, sector of 214
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-92.5% · 20 pct, sector of 188
Financial health
38
Inputs
  • Debt to equity0.18x · 61 pct, sector of 159
  • Cash flow to debt-7.08x · 15 pct, sector of 150
Growth
39
Inputs
  • Revenue growth, YoY+20.3% · 73 pct, sector of 219
  • Backlog growth, YoY-23.8% · 6 pct, sector of 37
Institutional and government
47
Inputs
  • Funds adding, latest quarter59 · 47 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
53
Inputs
  • Short interest, % of float+9.1% · 25 pct, sector of 241
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+5.3% · 81 pct, sector of 198
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies